Subjects:
Free Research Articles
In the article beginning on page 2391 in the 19 May 2016 issue, there are errors in the text and in Tables 1 and 10.
In Table 1 (page 2392), the entry “Blastic plasmacytoid dendritic cell neoplasm” was omitted. The corrected table is shown below.
Table 1
WHO classification of myeloid neoplasms and acute leukemia
| WHO myeloid neoplasm and acute leukemia classification . |
|---|
| Myeloproliferative neoplasms (MPN) |
| Chronic myeloid leukemia (CML), BCR-ABL1+ |
| Chronic neutrophilic leukemia (CNL) |
| Polycythemia vera (PV) |
| Primary myelofibrosis (PMF) |
| PMF, prefibrotic/early stage |
| PMF, overt fibrotic stage |
| Essential thrombocythemia (ET) |
| Chronic eosinophilic leukemia, not otherwise specified (NOS) |
| MPN, unclassifiable |
| Mastocytosis |
| Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2 |
| Myeloid/lymphoid neoplasms with PDGFRA rearrangement |
| Myeloid/lymphoid neoplasms with PDGFRB rearrangement |
| Myeloid/lymphoid neoplasms with FGFR1 rearrangement |
| Provisional entity: Myeloid/lymphoid neoplasms with PCM1-JAK2 |
| Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) |
| Chronic myelomonocytic leukemia (CMML) |
| Atypical chronic myeloid leukemia (aCML), BCR-ABL1− |
| Juvenile myelomonocytic leukemia (JMML) |
| MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) |
| MDS/MPN, unclassifiable |
| Myelodysplastic syndromes (MDS) |
| MDS with single lineage dysplasia |
| MDS with ring sideroblasts (MDS-RS) |
| MDS-RS and single lineage dysplasia |
| MDS-RS and multilineage dysplasia |
| MDS with multilineage dysplasia |
| MDS with excess blasts |
| MDS with isolated del(5q) |
| MDS, unclassifiable |
| Provisional entity: Refractory cytopenia of childhood |
| Myeloid neoplasms with germ line predisposition |
| Acute myeloid leukemia (AML) and related neoplasms |
| AML with recurrent genetic abnormalities |
| AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1 |
| AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11 |
| APL with PML-RARA |
| AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A |
| AML with t(6;9)(p23;q34.1);DEK-NUP214 |
| AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM |
| AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1 |
| Provisional entity: AML with BCR-ABL1 |
| AML with mutated NPM1 |
| AML with biallelic mutations of CEBPA |
| Provisional entity: AML with mutated RUNX1 |
| AML with myelodysplasia-related changes |
| Therapy-related myeloid neoplasms |
| AML, NOS |
| AML with minimal differentiation |
| AML without maturation |
| AML with maturation |
| Acute myelomonocytic leukemia |
| Acute monoblastic/monocytic leukemia |
| Pure erythroid leukemia |
| Acute megakaryoblastic leukemia |
| Acute basophilic leukemia |
| Acute panmyelosis with myelofibrosis |
| Myeloid sarcoma |
| Myeloid proliferations related to Down syndrome |
| Transient abnormal myelopoiesis (TAM) |
| Myeloid leukemia associated with Down syndrome |
| Blastic plasmacytoid dendritic cell neoplasm |
| Acute leukemias of ambiguous lineage |
| Acute undifferentiated leukemia |
| Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 |
| MPAL with t(v;11q23.3); KMT2A rearranged |
| MPAL, B/myeloid, NOS |
| MPAL, T/myeloid, NOS |
| B-lymphoblastic leukemia/lymphoma |
| B-lymphoblastic leukemia/lymphoma, NOS |
| B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities |
| B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2);BCR-ABL1 |
| B-lymphoblastic leukemia/lymphoma with t(v;11q23.3);KMT2A rearranged |
| B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1 |
| B-lymphoblastic leukemia/lymphoma with hyperdiploidy |
| B-lymphoblastic leukemia/lymphoma with hypodiploidy |
| B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3) IL3-IGH |
| B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3);TCF3-PBX1 |
| Provisional entity: B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like |
| Provisional entity: B-lymphoblastic leukemia/lymphoma with iAMP21 |
| T-lymphoblastic leukemia/lymphoma |
| Provisional entity: Early T-cell precursor lymphoblastic leukemia |
| Provisional entity: Natural killer (NK) cell lymphoblastic leukemia/lymphoma |
| WHO myeloid neoplasm and acute leukemia classification . |
|---|
| Myeloproliferative neoplasms (MPN) |
| Chronic myeloid leukemia (CML), BCR-ABL1+ |
| Chronic neutrophilic leukemia (CNL) |
| Polycythemia vera (PV) |
| Primary myelofibrosis (PMF) |
| PMF, prefibrotic/early stage |
| PMF, overt fibrotic stage |
| Essential thrombocythemia (ET) |
| Chronic eosinophilic leukemia, not otherwise specified (NOS) |
| MPN, unclassifiable |
| Mastocytosis |
| Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2 |
| Myeloid/lymphoid neoplasms with PDGFRA rearrangement |
| Myeloid/lymphoid neoplasms with PDGFRB rearrangement |
| Myeloid/lymphoid neoplasms with FGFR1 rearrangement |
| Provisional entity: Myeloid/lymphoid neoplasms with PCM1-JAK2 |
| Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) |
| Chronic myelomonocytic leukemia (CMML) |
| Atypical chronic myeloid leukemia (aCML), BCR-ABL1− |
| Juvenile myelomonocytic leukemia (JMML) |
| MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) |
| MDS/MPN, unclassifiable |
| Myelodysplastic syndromes (MDS) |
| MDS with single lineage dysplasia |
| MDS with ring sideroblasts (MDS-RS) |
| MDS-RS and single lineage dysplasia |
| MDS-RS and multilineage dysplasia |
| MDS with multilineage dysplasia |
| MDS with excess blasts |
| MDS with isolated del(5q) |
| MDS, unclassifiable |
| Provisional entity: Refractory cytopenia of childhood |
| Myeloid neoplasms with germ line predisposition |
| Acute myeloid leukemia (AML) and related neoplasms |
| AML with recurrent genetic abnormalities |
| AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1 |
| AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11 |
| APL with PML-RARA |
| AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A |
| AML with t(6;9)(p23;q34.1);DEK-NUP214 |
| AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM |
| AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1 |
| Provisional entity: AML with BCR-ABL1 |
| AML with mutated NPM1 |
| AML with biallelic mutations of CEBPA |
| Provisional entity: AML with mutated RUNX1 |
| AML with myelodysplasia-related changes |
| Therapy-related myeloid neoplasms |
| AML, NOS |
| AML with minimal differentiation |
| AML without maturation |
| AML with maturation |
| Acute myelomonocytic leukemia |
| Acute monoblastic/monocytic leukemia |
| Pure erythroid leukemia |
| Acute megakaryoblastic leukemia |
| Acute basophilic leukemia |
| Acute panmyelosis with myelofibrosis |
| Myeloid sarcoma |
| Myeloid proliferations related to Down syndrome |
| Transient abnormal myelopoiesis (TAM) |
| Myeloid leukemia associated with Down syndrome |
| Blastic plasmacytoid dendritic cell neoplasm |
| Acute leukemias of ambiguous lineage |
| Acute undifferentiated leukemia |
| Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 |
| MPAL with t(v;11q23.3); KMT2A rearranged |
| MPAL, B/myeloid, NOS |
| MPAL, T/myeloid, NOS |
| B-lymphoblastic leukemia/lymphoma |
| B-lymphoblastic leukemia/lymphoma, NOS |
| B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities |
| B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2);BCR-ABL1 |
| B-lymphoblastic leukemia/lymphoma with t(v;11q23.3);KMT2A rearranged |
| B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1 |
| B-lymphoblastic leukemia/lymphoma with hyperdiploidy |
| B-lymphoblastic leukemia/lymphoma with hypodiploidy |
| B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3) IL3-IGH |
| B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3);TCF3-PBX1 |
| Provisional entity: B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like |
| Provisional entity: B-lymphoblastic leukemia/lymphoma with iAMP21 |
| T-lymphoblastic leukemia/lymphoma |
| Provisional entity: Early T-cell precursor lymphoblastic leukemia |
| Provisional entity: Natural killer (NK) cell lymphoblastic leukemia/lymphoma |
On page 2393, in line 5 of the first paragraph in the right column, “t(8;9)(p22;q24.1);PCM1-JAK2” should read, “t(8;9)(p22;p24.1);PCM1-JAK2.”
In Table 10 (page 2397), column 2, in the information for PCM1-JAK2, “Often presents with T-LBL or B-ALL” should read “Rarely presents with T-LBL or B-ALL.” In column 3, in the information for PDGFRB, “t(5;12)(q31∼33;p12)” should read “t(5;12)(q32;p13.2).” In column 3, in the information for FGFR1, “Translocations of 8p11” should read “Translocations of 8p11.2.” The corrected table is shown below.
Table 10
Molecular genetic abnormalities in myeloid/lymphoid neoplasms associated with eosinophilia
| Disease . | Presentation . | Genetics . | Treatment . |
|---|---|---|---|
| PDGFRA | Eosinophilia | Cryptic deletion at 4q12 | Respond to TKI |
| ↑Serum tryptase | FIP1L1-PDGFRA, at least 66 other partners | ||
| ↑Marrow mast cells | |||
| PDGFRB | Eosinophilia | t(5;12)(q32;p13.2) ETV6-PDGFRB, at least 25 other partners | Respond to TKI |
| Monocytosis mimicking CMML | |||
| FGFR1 | Eosinophilia | Translocations of 8p11.2 | Poor prognosis; do not respond to TKI |
| Often presents with T-ALL or AML | FGFR1-various partners | ||
| PCM1-JAK2 | Eosinophilia | t(8;9)(p22;p24.1) PCM1-JAK2 | May respond to JAK2 inhibitors |
| Rarely presents with T-LBL or B-ALL | |||
| Bone marrow shows left-shifted erythroid predominance and lymphoid aggregates |
| Disease . | Presentation . | Genetics . | Treatment . |
|---|---|---|---|
| PDGFRA | Eosinophilia | Cryptic deletion at 4q12 | Respond to TKI |
| ↑Serum tryptase | FIP1L1-PDGFRA, at least 66 other partners | ||
| ↑Marrow mast cells | |||
| PDGFRB | Eosinophilia | t(5;12)(q32;p13.2) ETV6-PDGFRB, at least 25 other partners | Respond to TKI |
| Monocytosis mimicking CMML | |||
| FGFR1 | Eosinophilia | Translocations of 8p11.2 | Poor prognosis; do not respond to TKI |
| Often presents with T-ALL or AML | FGFR1-various partners | ||
| PCM1-JAK2 | Eosinophilia | t(8;9)(p22;p24.1) PCM1-JAK2 | May respond to JAK2 inhibitors |
| Rarely presents with T-LBL or B-ALL | |||
| Bone marrow shows left-shifted erythroid predominance and lymphoid aggregates |
↑, Increased.
The errors have been corrected in the online version, which now differs from the print version.
© 2016 by The American Society of Hematology
2016
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal